Miracell Receives Minister of Trade, Industry and Energy Award for New Medical Technology Research and Development
“Smart Mcell 2″ Development Achievements Highly Recognized”
Miracell CEO Shin Hyun-soon received a commendation from the Minister of Trade, Industry and Energy at the opening ceremony of “KIMES 2022” held at COEX on March 10th in recognition of his contributions to the advancement of the medical device industry through research and development of new medical technologies.
KIMES annually recognizes and awards individuals who have contributed to the advancement of the medical device industry and exports, in an effort to elevate the standards of international medical device and hospital equipment exhibitions and to promote the growth of the medical device industry.
This year, Miracell was selected as the recipient of the Minister of Trade, Industry and Energy commendation for its “Smart M-cell 2,” a cutting-edge stem cell extraction system, in recognition of its achievements in new medical technology research and development.
The “Smart M-cell 2,” a system capable of selective stem cell collection, is a regenerative medical device that extracts large quantities of automatically separated stem cells from bone marrow and blood extracted from the body through centrifugation with minimal manipulation.
Miracell received NET New Health Technology certification from the Ministry of Health and Welfare for its Smart Mcell 2 and was selected as a national representative for innovative companies in the health/diagnosis sector.
Miracell’s stem cell extraction system, already used for therapeutic purposes at major hospitals in Korea, recently received “Innovative Product Designation Certification” from the government,
enabling it to be supplied to national and public hospitals and other government institutions through the Public Procurement Service.
Miracell is the first company in Korea to have four new medical technology assessments from the Ministry of Health and Welfare,
including autologous stem cell therapy for cartilage defects, acute myocardial infarction, and diabetic critical limb ischemia. It is a stem cell specialist company with numerous patent applications in 15 countries, including two in the EU.
Miracell CEO Shin Hyun-soon said in his acceptance speech, “For over 15 years, we have dedicated ourselves to researching stem cells and developing a system capable of selectively isolating them for therapeutic use. To enhance cell viability, recovery rates, and cell health, we were the first in the world to incorporate an LED laser. The results were very successful. I am delighted that the government has recognized our outstanding technology.”
CEO Shin continued, “In an aging society, personalized disease prediction, prevention, healthcare, and even disease treatment are becoming increasingly important. Therefore, we will do our best to promote Miracell’s unique technology in the global bio-regenerative market.”
Following its participation in the Arab Health Fair in February, Miracell plans to promote the Smart Mcell 2 in the first half of the year by participating in booths at the 2022 Cosmoprof Bologna, Italy (April 29-May 2) and the São Paulo Medical Device Exhibition (May 17-20).
Meanwhile, Miracell, which also operates a stem cell research center, is also focusing its efforts on stem cell-based treatments for intractable diseases, such as early-stage dementia, in collaboration with domestic university hospitals.